Male breast cancer is a rare disease with an increasing trend. Due to limited information especially about the genetic basis of the disease in Iran and the lower age of its onset, the disease requires more attention. The aim of this study was to screen the male patients with breast cancer for BRCA mutations as well as tissue markers of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor (HER-2) and cytokeratin 5/6 (CK5/6). Ten Iranian males with breast cancer were selected regardless of their histologic subtypes, age and family history from patients referred to Mehrad, Day and Parsian hospitals in Tehran, Iran, during a two-year period. Paraffin blocks of the tumoral regions were tested for ER, PR, HER-2 and CK5/6 immunostaining. DNA extraction was carried out on the EDTA blood samples followed by Sanger sequencing.
reast cancer is the most prevalent malignancy affecting women (1, 2) . The disease is rare in males, accounting for 1% of all breast cancer cases (3) (4) (5) but recently a significant increasing rate from 0.86 to 1.08 cases per 100,000 populations has been reported (5-7). There are many studies reported from Iran on female breast cancer (FBC) but male breast cancer (MBC) still needs to be studied (8, 9) . (10) . In Iran, MBC accounts for 0.65% of all cases of malignancy in men. There are 6674 incident cases of breast cancer diagnosed in Iran in 2007 of whom 3.26% were men (11) . Due to its low incidence, there are few studies and limited information on this subject especially about the genetic etiology of the disease.
Furthermore, the average age of male breast cancer and female breast cancer in Iran is lower than developed countries (11) , and men are usually diagnosed with breast cancer at more advanced stages often with lymph node metastasis (3, 12) .
Several risk factors including advancing age, positive family history and mutations in susceptibility genes such as BRCA1 and especially BRCA2 are considered for the study of male breast cancer (10) .
BRCA1 and BRCA2 are tumor suppressor genes, located on 17q21and 13q12 loci with 24 and 27 exons, respectively. These genes normally participate in the repair of damaged DNA by homologous recombination. Although BRCA2 is the most clearly associated gene, BRCA1 mutation is also considered in familial and even sporadic cases of male breast cancer (4, 5, 13) . According to some studies, BRCA2 mutations occur in 4-16% of male breast cancer patients. However, BRCA1 mutations are much less common and 0-4% of men with breast cancer carry these mutations (14) .
BRCA1 mutations as a prognostic factor also have great importance, as carriers of these mutations have a poorer prognosis compared to other patients.
Mutation in BRCA2 also has a special significance as the mutation carriers can be diagnosed with breast cancer at lower age and has a shorter survival (13) . In comparison with BRCA1 mutations, BRCA2 mutations have major significance in MBC patients (4, 5, 13) . Patients with mutation in BRCA2 are predisposed to breast cancer and other malignancies such as pancreatic, prostate cancer and melanoma. Molecular subtypes of MBC are similar to FBC (4, 11) . According to several studies, MBC seems to be more hormone receptor positive (luminal A subtype) (3, 13, 14) , than FBC. The main aim of this study was to screen the male patients with breast cancer for BRCA1 and BRCA2 mutations as well as the status of tissue tumor markers including ER, PR, HER-2 and basal marker (CK5/6). We also investigated the relationship between the BRCA1 and BRCA2 mutations and the tissue markers' status.
Materials and methods

Patient selection and sampling
In this cross-sectional study, 10 Interpretation of the results was performed using the classification method based on tissue tumor markers ( Table 1) . less than 1% staining reveals negative result.
Concerning HER-2 staining, HER-2/CEN17 ratio< 1.8= negative, ratio= 1.8-2.2 means equivocal and ratio> 2.2 means positive.
Gene sequencing
Genomic DNA was extracted from the blood samples using salting out method. The quality and quantity of DNA was determined by reading the optical density of the sample at 260 nm and 280
nm. Primers for BRCA1 and BRCA2 genes were designed by primer 3 and UCSC genome browser.
Self-dimers, heterodimers and the melting temperature of the primers were also checked by oligo analyzer site (https:// www. idtdna.com/ calc/ analyzer).
In BRCA1, exon 10 and 24 were separated into 6 and 3 fragments, respectively. In BRCA2, exons11, 10, and 27 were separated into 9, 3, and 2 fragments respectively. DNA was amplified by polymerase chain reaction (PCR) technique.
Mutation analysis was performed by direct
DNA sequencing of all the exons of BRCA1 and
BRCA2. The partial flanking intronic sequences
were obtained using codon code aligner and Gene runner softwares
Results
Immunohistochemical analyzes
In this study, we screened 10 Iranian men with breast cancer in order to find any mutation in BRCA 
Mutation analysis
Following PCR amplification and sequencing of BRCA1 and BRCA2, in 10 males with breast cancer, their variants and polymorphisms were detected. Further information, including the exon number, base changes and frequency of these variants in 10 patients, are shown in Tables 2 and 3 for the BRCA1 and BRCA2, respectively. a b Table 5 .
Discussion
In this study, 10 males with breast cancer were screened for mutations in BRCA1 and BRCA2.
Besides, the patients were characterized for immunohistochemical features such as ER, PR, Her-2, and CK5/6 tissue tumor markers. In one patient, mutation in exon 18 of BRCA1 was detected. Furthermore, another patient has a nonsense mutation in exon 25 of BRCA2.
Moreover, several variants and polymorphisms associated with BRCA1 and BRCA2 were found, also some features correlated to those, such as the exon number, base changes and frequency of these variants, were summarized in Tables 3 and 4 . As the purpose of the current study was mutation screening in BRCA1 and BRCA2, associated variants were identified and assessed in order to note whether they were disease causing. Then mutation screening was followed until a mutation was found and confirmed by some known softwares and databases. Results of IHC technique for HER-2 and CK5/6 markers of all patients and ER and PR markers for two patients were negative.
Previous studies have indicated that mutation in BRCA2 in MBC is more common than BRCA1, but our findings could not conclude such results due to the small sample size. According to a similar study by Deb and his colleagues in Australia in (18) . While this project is a pioneer study based on genetic and histopathologic aspects of MBC in Iran, there is still a great need to study the genetic basis of MBC.
It should be mentioned that the main problems of this project were: "case finding" and "tiny tissue samples". Considering the low prevalence of the disease around the world, especially in Iran, despite searching four hospitals to find males with breast cancer, and due to the problems such as lack of cooperation of the patients and their families, finally a small population of only 10 qualified cases were allocated for the study. According to the rarity of MBC and its increasing rate in the world, it seems to be necessary to perform studies with larger sample size. We believe that general education for the early diagnosis of breast cancer in males in order to increase their awareness of this disease, and also promotion of the quality of diagnostic methods in Iran are necessary.
